Safety Assessment of Ritlecitinib Based on the FDA Adverse Event Reporting System (FAERS) Database: A Real-World Pharmacovigilance Study. Huang Y, Ke C, Chen M. J Dermatol 2025;52:1561-1569.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Huang Y, Ke C, Chen M. Safety Assessment of Ritlecitinib Based on the FDA Adverse Event Reporting System (FAERS) Database: A Real-World Pharmacovigilance Study. J Dermatol 2025;52:1561-1569.
PMID: 40715010